Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
暂无分享,去创建一个
M. C. Ditto | V. Bruzzese | S. Parisi | E. Fusaro | V. Nucera | A. Becciolini | R. Foti | C. Salvarani | S. Bernardi | A. Volpe | A. Ianniello | G. Ferrero | F. Girelli | F. Lumetti | G. Sandri | R. Andracco | P. Scolieri | A. Farina | M. Paroli | A. Ariani | D. Santilli | E. Bravi | V. Franchina | P. Del Medico | E. Visalli | E. Arrigoni | G. Amato | R. Caccavale | A. Marchetta | M. Colina | N. Mansueto | F. De Lucia | G. Lucchini | A. M. Molica Colella | I. Platé | E. D. Donato | F. Molica Colella
[1] V. Bruzzese,et al. Apremilast retention rate in clinical practice: observations from an Italian multi-center study , 2022, Clinical Rheumatology.
[2] D. Gladman,et al. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis , 2022, The Journal of Rheumatology.
[3] K. de Vlam,et al. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study , 2022, Advances in Therapy.
[4] A. Ogdie,et al. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results , 2020, The Journal of Rheumatology.
[5] L. Coates,et al. Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations , 2020, Arthritis care & research.
[6] R. Lucchetti,et al. Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study , 2019, Clinical Rheumatology.
[7] C. Edwards,et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial , 2018, Rheumatology.
[8] H. Marzo-Ortega,et al. Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. , 2018, Rheumatology.
[9] L. Coates,et al. Psoriatic arthritis: state of the art review , 2017, Clinical medicine.
[10] M. Cutolo,et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.
[11] C. Edwards,et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.
[12] M Cutolo,et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.
[13] D. Gladman,et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.
[14] A. Kavanaugh,et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis , 2010, Annals of the rheumatic diseases.
[15] Dafna Gladman,et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.
[16] F. Wolfe,et al. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues , 2004, Annals of the rheumatic diseases.
[17] R. Caporali,et al. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. , 2019, Clinical and experimental rheumatology.